Immunomic Therapeutics (ITI) Delivering Closing Keynote Address at Wharton DC Innovation Summit

Monday, April 25, 2016 General News J E 4
-- CEO William Hearl, Ph.D. will share ITI's novel angel investment funding approach - a refreshing new model for biotech innovators

WASHINGTON, April 25, 2016 /PRNewswire/ -- On Wednesday, ITI Chief Executive Officer Bill Hearl, PhD will deliver the closing keynote remarks at the third annual Wharton DC Innovation Summit. His talk is titled "From Innovation to ROI: A Biotech Success Story" and will focus on ITI's unique investment strategy and how the company developed an innovative vaccine technology from Johns Hopkins and turned it into a $300 million cash licensing deal and delivered a five-fold return for its investors.

"I am pleased to participate in the esteemed Wharton DC Innovation conference and share what I've learned about licensing new vaccine technology through a limited investment model," said ITI Chief Executive Officer Bill Hearl, PhD. "Replicating our regional market approach could secure new possibilities for important medical developments like the LAMP-Vax technology platform, which has the potential revolutionize vaccine efficacy through immune system re-education."

The Third Annual Wharton Innovation Summit, Raise Your Innovation IQ, is a two-day event taking place Tues., April 26Wed., April 27 at FHI 360 located at 1825 Connecticut Avenue NW in Washington, D.C.

Additional speakers include author Chris Surdak discussing Big Data, Susan Dentzer (NEHI) talking about healthcare's tough new issues, Google's Gopi Kallayil sharing new venture lessons and the "Fathers of the Internet," Vint Cerf and Bob Kahn, co-inventors of the key internet protocol, sharing what they know about the future internet challenges.

Follow the conversation at #WDCInnovation2016

About Immunomic TherapeuticsImmunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These disruptive technologies have the potential to fundamentally improve how we use immunotherapy for cancer, allergies and animal health.  Headquartered in Hershey, PA with lab facilities in Rockville, MD, ITI has entered into a significant licensing agreement with Astellas Pharma Inc., to explore the use of LAMP-vax, a next-generation immunotherapy platform, for use to prevent and treat allergic diseases. ITI believes that LAMP-based nucleic acid immunotherapy may have the potential to broaden the current use of cancer immunotherapy.  Preclinical data is currently being developed to explore how LAMP nucleic acid constructs could both amplify and activate the immune response in highly immunogenic tumor types and also be used to create robust immune responses to tumor types that otherwise do not provoke an immune response. For information about ITI and LAMP Technology, visit


To view the original version on PR Newswire, visit:

SOURCE Immunomic Therapeutics, Inc.



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
New Report Finds 340B Hospitals Have Low Complianc...
Heptares Scientists Solve Structures of GLP-1 and ...